List of Excipients in Branded Drug UP AND UP NAPROXEN SODIUM

Generic Drugs Containing UP AND UP NAPROXEN SODIUM

Company	Ingredient	NDC	Excipient
Target Corporation	naproxen sodium	11673-368	CELLULOSE, MICROCRYSTALLINE
Target Corporation	naproxen sodium	11673-368	FD&C BLUE NO. 2 ALUMINUM LAKE
Target Corporation	naproxen sodium	11673-368	HYPROMELLOSE
Target Corporation	naproxen sodium	11673-368	MAGNESIUM STEARATE
Target Corporation	naproxen sodium	11673-368	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in UP AND UP NAPROXEN SODIUM?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	FD&C BLUE NO. 2 ALUMINUM LAKE
2	HYPROMELLOSE
2	MAGNESIUM STEARATE
2	POLYETHYLENE GLYCOL

Up & Up Naproxen Sodium Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Up & Up Naproxen Sodium is an over-the-counter, store-brand version of naproxen sodium 220 mg. Its commercial value comes from low-cost manufacturing, stable tablet performance, recognizable private-label branding, and broad retail distribution rather than patent exclusivity. The strongest excipient opportunities are improved swallowability, faster disintegration, lower tablet weight, reduced coating cost, and differentiated dosage forms such as liquid gels, orally disintegrating tablets, and pediatric presentations.

The product is regulated under the FDA’s OTC monograph framework for internal analgesic, antipyretic, and antirheumatic products. Naproxen sodium is an established active ingredient with no meaningful remaining composition-of-matter exclusivity for this OTC product category.[1,2]

What is Up & Up Naproxen Sodium?

Up & Up Naproxen Sodium is a Target private-label analgesic containing naproxen sodium, typically at a 220 mg strength corresponding to 200 mg naproxen. The product is marketed for temporary relief of minor aches and pains and reduction of fever.

Attribute	Commercial assessment
Brand	Up & Up
Retailer	Target Corporation
Active ingredient	Naproxen sodium
Common OTC strength	220 mg
Therapeutic category	NSAID analgesic and antipyretic
Regulatory pathway	OTC monograph
Prescription requirement	No
Patent dependence	Low
Primary commercial advantage	Retail price, distribution, and private-label positioning
Main product risks	NSAID safety labeling, gastrointestinal risk, renal warnings, cardiovascular warnings, and supply continuity

Naproxen sodium is the salt form of naproxen. Its principal formulation advantage is higher aqueous solubility than the free acid, which can support faster dissolution and onset. The drug remains subject to the pharmacologic and safety limitations of nonsteroidal anti-inflammatory drugs, including gastrointestinal bleeding, cardiovascular events, renal impairment, and contraindications related to pregnancy and hypersensitivity.[1,3]

What excipients are used in Up & Up Naproxen Sodium?

The marketed tablet uses a conventional immediate-release tablet architecture. Public product labeling identifies inactive ingredients used for tablet formation, disintegration, lubrication, coating, appearance, and processing. Exact excipient composition can vary by manufacturer, site, NDC, and manufacturing revision.

Typical functional categories include:

Excipient function	Likely formulation role
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Povidone	Binder
Magnesium stearate	Lubricant
Talc	Processing aid and coating component
Hypromellose	Film-forming polymer
Polyethylene glycol	Coating plasticizer
Titanium dioxide or approved colorants	Opacity and appearance
Sodium lauryl sulfate, where used	Wetting and dispersion aid

The formulation objective is not maximum dissolution speed alone. It must balance hardness, friability, coating integrity, dissolution, packaging stability, production yield, and cost. A naproxen sodium tablet that disintegrates too rapidly can create processing and friability problems. Excessive lubrication can slow dissolution. High compression force can produce a durable tablet but delay liquid penetration.

The exact current inactive-ingredient listing should be taken from the applicable FDA label and NDC record before a supplier, licensing, or litigation decision is made.[4]

How does the excipient strategy affect naproxen sodium performance?

The principal formulation problem is achieving rapid, reproducible release from a relatively high-dose tablet while maintaining mechanical strength.

Disintegration and dissolution

Croscarmellose sodium or an equivalent superdisintegrant can promote rapid tablet breakup through swelling and wicking. Its concentration, particle size, and intra-granular versus extra-granular placement affect dissolution. Excessive levels can reduce compactibility or increase moisture sensitivity.

Microcrystalline cellulose supports direct compression and contributes to tablet strength. Its grade affects flow, compaction, lubricant sensitivity, and disintegration. A supplier change can therefore require comparative dissolution and physical-property testing even when the excipient is pharmacopeial grade.

Lubrication control

Magnesium stearate is commercially efficient but sensitive to blending time and concentration. Over-lubrication can create hydrophobic particle surfaces, reduce tensile strength, and slow dissolution. A shorter lubrication cycle, lower lubricant concentration, or alternative lubricant can improve release consistency without changing the active ingredient.

Film coating

Film coating supports identification, swallowing, appearance, and protection from abrasion. For a private-label product, the coating also helps create visual similarity with adjacent Up & Up analgesic products.

Cost reduction can come from:

• Lower coating weight gain.
• A more concentrated coating suspension.
• Reduced titanium dioxide or colorant loading.
• Faster spray rates with improved atomization.
• Use of a one-step aqueous film-coating system.
• Lower tablet friability before coating.

Coating changes require evaluation of dissolution, disintegration, moisture uptake, appearance, and packaging compatibility.

Moisture management

Naproxen sodium tablets must maintain physical stability during distribution through retail warehouses, delivery networks, and household storage. Excipient moisture content, packaging barrier properties, and tablet coating interact. High-barrier blister packaging may permit a lower-cost formulation, while bottles with desiccants can support bulk-count economics but increase packaging complexity.

What commercial opportunities exist for naproxen sodium excipients?

The largest opportunity is not a new naproxen sodium molecule. It is a lower-cost or better-performing delivery platform that can be sold to private-label retailers, contract manufacturers, or branded OTC companies.

1. Faster-onset immediate-release tablets

A formulation using optimized superdisintegrant placement, wetting control, and low-lubrication processing could support faster in vitro dissolution. The commercial claim would need to remain within permitted OTC labeling unless supported by appropriate regulatory evidence.

Potential value:

• Differentiation from standard store-brand tablets.
• Premium pricing for "fast relief" positioning.
• Improved consumer experience.
• Licensing opportunity for a formulation package or manufacturing process.

The commercial barrier is that faster dissolution does not automatically establish faster clinical analgesia. A clinical or regulatory substantiation strategy may be necessary for a meaningful onset-of-action claim.

2. Smaller or easier-to-swallow tablets

A higher-density excipient system can reduce tablet volume while preserving the 220 mg naproxen sodium dose. Candidate approaches include:

• Co-processed cellulose-based excipients.
• Improved-flow direct-compression carriers.
• Granulation systems with higher compactability.
• Reduced coating weight.
• More efficient tablet geometry.

A smaller tablet may increase adherence among older consumers and patients who have difficulty swallowing NSAID tablets. The primary technical risks are capping, lamination, friability, and reduced dissolution after higher compression.

3. Liquid gels and softgels

Naproxen sodium can be developed in a softgel or liquid-filled capsule using a solubilized or suspended formulation. Excipients may include polyethylene glycol vehicles, surfactants, co-solvents, and capsule-shell plasticizers.

Commercial advantages include:

• Easier swallowing.
• Premium positioning.
• Potentially faster dispersion than a conventional tablet.
• Strong differentiation from low-price tablets.

Risks include shell compatibility, precipitation, oxygen and moisture sensitivity, fill-weight control, leakage, and higher manufacturing cost. Softgels are more attractive for branded or premium private-label products than for the lowest-cost 100-count bottle.

4. Orally disintegrating tablets

An orally disintegrating naproxen sodium product could target consumers who have difficulty swallowing. The formulation would require taste masking because naproxen sodium has an undesirable taste profile.

Potential technologies include:

• Ion-exchange resin complexes.
• Polymer coating of drug particles.
• Lipid or wax taste-masking systems.
• Flavor and sweetener systems.
• Porous tablet matrices.
• Spray-dried composite particles.

The main barrier is dose size. A 220 mg naproxen sodium load is substantial for an orally disintegrating tablet. Taste masking and tablet size may limit commercial practicality.

5. Chewable or flavored dosage forms

Chewable products could expand use among consumers seeking convenience, but naproxen’s taste and NSAID safety profile make the format difficult. A chewable formulation would need robust taste masking, low residue, and strong child-resistant packaging. It would also require careful labeling to avoid accidental pediatric ingestion.

6. Dual-action analgesic products

A combination product containing naproxen sodium and acetaminophen could offer a differentiated pain-relief platform. The excipient challenge is managing two active ingredients with different dose, dissolution, and stability requirements.

A combination product would likely require a separate FDA regulatory strategy rather than simple substitution within an existing monograph product. It could face interaction concerns, dose-labeling complexity, and competitive pressure from existing combination analgesics.

What is the FDA regulatory status of Up & Up Naproxen Sodium?

Naproxen sodium 220 mg products are generally positioned as OTC internal analgesic products under FDA’s monograph framework. The FDA final rule for internal analgesic, antipyretic, and antirheumatic products identifies permitted active ingredients, indications, warnings, directions, and labeling conditions.[1]

A conventional Up & Up naproxen sodium tablet does not normally require a new drug application for routine monograph-compliant marketing. A formulation that changes the dosage form, indication, delivery profile, or labeling claim can require a different regulatory assessment.

Key regulatory distinctions are:

Product change	Likely regulatory implication
Excipient substitution within a conventional tablet	CMC and quality assessment; usually no new clinical program if monograph conditions remain satisfied
New tablet coating	Product quality, dissolution, stability, and labeling review
Liquid gel	New dosage-form and manufacturing assessment
Orally disintegrating tablet	Performance, taste, disintegration, stability, and labeling assessment
New combination product	Potentially separate regulatory pathway
Faster-onset claim	Substantiation beyond ordinary monograph compliance may be required
Pediatric formulation	Labeling, safety, dosing, and accidental-ingestion considerations

FDA’s inactive-ingredient database is relevant when assessing precedent for excipient type, route, and dosage form. The database does not by itself establish approval of a particular formulation or guarantee acceptance of a new concentration.[5]

What patents protect Up & Up Naproxen Sodium?

No publicly apparent patent estate is likely to protect the ordinary Up & Up naproxen sodium 220 mg tablet as a product. Naproxen and naproxen sodium have been marketed for decades, and routine immediate-release tablets are exposed to extensive prior art.

IP category	Risk level for conventional tablet	Commercial relevance
Naproxen composition of matter	Very low	Expired or commercially irrelevant
Naproxen sodium salt	Very low	Long-established technology
Standard immediate-release tablet	Low	Broad prior art
Specific excipient ratio	Low to moderate	Possible only if narrowly claimed
Fast-dissolving formulation	Moderate	More defensible if performance is unexpected
Liquid-filled capsule	Moderate	Dosage-form and vehicle claims may exist
Taste-masked dosage form	Moderate	Particle coating and matrix claims may be relevant
Manufacturing process	Moderate	Process claims may affect freedom to operate
Packaging system	Low to moderate	Relevant to barrier and stability innovation
Method of use	Low for ordinary OTC indications	New indication or dosing regimen may create exposure

The strongest patent opportunity would involve a narrow formulation or process that produces a measurable technical effect, such as materially faster dissolution, improved stability under high humidity, reduced tablet size, or effective taste masking. A patent directed only to replacing one conventional filler with another would face substantial obviousness risk.

When does naproxen sodium lose exclusivity?

Naproxen sodium has already lost meaningful pharmaceutical exclusivity for standard OTC tablet use. The relevant commercial protection is retailer branding, distribution, manufacturing scale, quality consistency, packaging, and shelf placement.

There is no standard branded-product exclusivity period that prevents generic or private-label naproxen sodium competition. OTC competitors can market monograph-compliant products without relying on an innovator patent estate.

The practical exclusivity timeline is therefore:

Milestone	Status
Original naproxen development	Historical
Prescription generic competition	Established
OTC naproxen sodium competition	Established
Store-brand entry	Established
Standard tablet patent barrier	Not material
New formulation exclusivity	Possible only through separate patent and regulatory work

How many patents cover Up & Up Naproxen Sodium?

For the conventional Up & Up product, the commercially relevant number is effectively zero for core active-ingredient protection. That does not mean every naproxen sodium product is free of third-party IP. A competitor must still review patents covering:

• Softgel fill vehicles.
• Particle-size engineering.
• Taste masking.
• Orally disintegrating matrices.
• Controlled-release systems.
• Combination analgesics.
• Specialized manufacturing equipment or processes.
• Packaging and moisture-control systems.

The FDA Orange Book is primarily relevant to approved prescription drug products and does not function as a complete patent register for ordinary OTC monograph products.[2] Patent clearance should therefore use USPTO records, WIPO databases, national registers, and relevant litigation searches rather than Orange Book data alone.

Are there Paragraph IV challenges involving Up & Up Naproxen Sodium?

A conventional OTC monograph product is not normally exposed to the ANDA Paragraph IV process in the same manner as an innovator prescription product. Paragraph IV litigation is designed for abbreviated new drug applications referencing listed drugs with Orange Book patent certifications.

Up & Up Naproxen Sodium is therefore unlikely to have a meaningful Paragraph IV litigation profile. Competitive entry usually occurs through OTC monograph compliance, private-label sourcing, or a prescription generic pathway for applicable products.

This distinction matters for investors and licensors. The absence of Paragraph IV litigation does not indicate strong exclusivity. It generally indicates that the product competes in a different regulatory structure.

What patent litigation affects naproxen sodium products?

The standard naproxen sodium tablet category has limited litigation risk compared with patented prescription medicines. Litigation exposure is more likely to arise from:

1. A branded reformulation with a specific delivery system.
2. A licensed softgel or liquid-filled capsule technology.
3. A combination product with a protected formulation.
4. Trade dress, trademark, or packaging disputes.
5. Manufacturing know-how or confidential supplier information.

Potential defendants include OTC manufacturers, contract manufacturers, private-label retailers, and formulation technology licensors. A supplier using a patented coating, encapsulation, or taste-masking platform can create indirect freedom-to-operate risk even when naproxen sodium itself is unpatented.

Which companies challenge Up & Up Naproxen Sodium?

The competitive field includes national brands, generic drug manufacturers, private-label retailers, and contract manufacturers. Relevant competitors include products sold under Aleve, generic naproxen sodium labels, Amazon Basic Care, CVS Health, Walgreens, Walmart Equate, and other retail brands.

Competitor type	Primary advantage	Excipient opportunity
National brand	Consumer recognition and advertising	Premium softgels and fast-relief formats
Generic manufacturer	Scale and low unit cost	Process optimization and supplier leverage
Retail private label	Shelf access and price	Smaller tablets, differentiated coatings, multipacks
Contract manufacturer	Flexible sourcing	Multi-client formulation platforms
Online retailer brand	Direct consumer data and fulfillment	Convenient dosage forms and subscription packaging

Up & Up’s principal competitive defense is Target’s retail network and private-label ecosystem. A new excipient technology must show a measurable consumer or manufacturing benefit to overcome the cost advantage of a conventional tablet.

What is the revenue exposure of Up & Up Naproxen Sodium?

Target does not publicly report revenue for individual Up & Up SKUs. Product-level revenue, gross margin, unit velocity, and supplier pricing are therefore not publicly established.

Commercial value can be assessed through:

• Store count and online availability.
• Count size and retail price.
• Shelf placement.
• Repeat purchase rates.
• Seasonal demand.
• Promotional frequency.
• Comparable national-brand pricing.
• Contract manufacturing volume.
• Retailer margin requirements.

The product is likely to have modest revenue per unit but potentially significant aggregate volume because naproxen sodium is a mature, frequently purchased OTC analgesic. Excipient cost reductions may produce meaningful margin gains at scale. A reduction of even a fraction of a cent per tablet can affect annual contribution when applied across large private-label volumes.

How strong is the patent estate for Up & Up Naproxen Sodium?

The patent estate is weak for the conventional product and potentially stronger for differentiated delivery systems.

Estate component	Strength
Active ingredient	Weak
Standard tablet	Weak
Conventional excipients	Weak
Novel dissolution platform	Moderate
Taste masking	Moderate
Softgel delivery	Moderate
New combination product	Moderate, depending on claims
Manufacturing process	Fact-specific
Brand and trade dress	Separate trademark exposure

The best licensing opportunity is a formulation platform that can be adapted across naproxen sodium, ibuprofen, acetaminophen, and other OTC actives. A platform with demonstrated scale-up, stability, and dissolution data has greater commercial value than a single narrow naproxen patent.

What manufacturing and IP barriers affect commercial entry?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

• Consistent powder flow at high active load.
• Control of tablet weight and content uniformity.
• Lubrication sensitivity.
• Coating defects.
• Dissolution drift after scale-up.
• Moisture exposure during packaging.
• Supplier variability.
• Equipment changeover and cleaning validation.
• Foreign-matter and cross-contamination controls.

IP and commercial barriers

• Third-party delivery-system patents.
• Exclusive contract-manufacturing arrangements.
• Retailer qualification requirements.
• Approved supplier status.
• Existing tooling and packaging specifications.
• Minimum order quantities.
• Stability data ownership.
• Confidential process parameters.
• Trademark and trade-dress restrictions.

A new excipient supplier must compete on delivered cost and quality performance, not ingredient price alone. The relevant economic calculation includes validation, technical transfer, regulatory documentation, inventory, rejected batches, and supply interruption risk.

What licensing deals could create value?

Potential licensing structures include:

1. A formulation license for rapid-dissolution naproxen sodium tablets.
2. A platform license covering multiple OTC analgesics.
3. A co-development agreement with a private-label retailer.
4. A contract manufacturing agreement with exclusive regional rights.
5. A supply agreement tied to a proprietary co-processed excipient.
6. A softgel or taste-masking technology license.
7. A packaging and moisture-control collaboration.

Royalty potential is highest where the technology supports a premium claim or reduces manufacturing cost without requiring major capital investment. A formulation that only replaces an inexpensive conventional excipient will usually have limited royalty value unless it materially improves yield, dissolution, or stability.

What generic launch scenarios exist for naproxen sodium?

Because ordinary naproxen sodium tablets are mature OTC products, launch scenarios are straightforward.

Launch scenario	Probability	Commercial outcome
Low-cost conventional tablet	High	Competes on price and distribution
Smaller tablet	Moderate	Targets swallowability and packaging efficiency
Faster-dissolution tablet	Moderate	Supports differentiated marketing if substantiated
Liquid gel	Moderate	Higher price and manufacturing cost
Orally disintegrating tablet	Low to moderate	Strong differentiation but taste and dose barriers
Pediatric or chewable product	Low	Safety, taste, and labeling complexity
Combination analgesic	Moderate	Larger regulatory and clinical burden

The most practical near-term opportunity is an optimized immediate-release tablet or liquid gel. An orally disintegrating formulation has greater technical risk because of dose loading and taste masking.

Key Takeaways

• Up & Up Naproxen Sodium is a mature OTC private-label product based on naproxen sodium 220 mg.
• The conventional tablet has little or no meaningful active-ingredient patent protection.
• FDA monograph compliance, not Paragraph IV litigation, is the central regulatory framework.
• Excipient value lies in faster disintegration, smaller tablets, coating efficiency, moisture stability, and manufacturing yield.
• Conventional excipient substitution offers limited patent strength unless it produces an unexpected technical result.
• Liquid gels and taste-masked dosage forms provide greater differentiation but carry higher manufacturing and regulatory costs.
• Target does not publicly disclose SKU-level revenue, so commercial valuation should rely on distribution, pricing, unit volume, and manufacturing economics.
• The strongest licensing opportunity is a scalable platform applicable to several OTC analgesics rather than a narrow naproxen-only formulation.

FAQs

Is Up & Up Naproxen Sodium a generic drug?

It is a private-label OTC product rather than a branded prescription generic. It competes with national brands and other store brands under the FDA’s OTC monograph framework.

Can a new excipient create patent protection for naproxen sodium?

Yes, but the claim must usually cover a specific formulation, process, or measurable performance advantage. Merely substituting one conventional filler for another is unlikely to produce strong patent protection.

Is naproxen sodium more soluble than naproxen?

Yes. Naproxen sodium is the salt form and generally has higher aqueous solubility than naproxen free acid, supporting immediate-release dosage forms.

Would a liquid gel be commercially superior to an Up & Up tablet?

It could support premium pricing and easier swallowing, but it would have higher manufacturing, packaging, stability, and quality-control costs. Commercial superiority depends on consumer willingness to pay and retailer margin requirements.

Does the Orange Book list Up & Up Naproxen Sodium patents?

The Orange Book is not the primary patent source for a conventional OTC monograph product. Patent review should focus on relevant formulation, delivery-system, manufacturing, and packaging claims in national and international patent databases.

References

1. U.S. Food and Drug Administration. (2022). Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: 21 C.F.R. Part 343. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/part-343

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2024). Naproxen sodium drug product labeling. DailyMed. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. Target Corporation. (n.d.). Up & Up naproxen sodium tablet product labeling. DailyMed. National Library of Medicine. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm